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Background: CT screening for lung cancer is effective in reducing mortality, but there are areas of concern,
including a positive predictive value of 4% and development of interval cancers. A blood test that could manage
these limitations would be useful, but development of such tests has been impaired by variations in blood
collection that may lead to poor reproducibility across populations.
Results: Blood-based proteomic profiles were generated with SOMAscan technology, which measured 1033
proteins. First, preanalytic variability was evaluated with Sample Mapping Vectors (SMV), which are panels of
proteins that detect confounders in protein levels related to sample collection. A subset of well collected serum
samples not influenced by preanalytic variability was selected for discovery of lung cancer biomarkers. The impact
of sample collection variation on these candidate markers was tested in the subset of samples with higher SMV
scores so that the most robust markers could be used to create disease classifiers. The discovery sample set (n = 363)
was from a multi-center study of 94 non-small cell lung cancer (NSCLC) cases and 269 long-term smokers and benign
pulmonary nodule controls. The analysis resulted in a 7-marker panel with an AUC of 0.85 for all cases (68%
adenocarcinoma, 32% squamous) and an AUC of 0.93 for squamous cell carcinoma in particular. This panel was
validated by making blinded predictions in two independent cohorts (n = 138 in the first validation and n = 135
in the second). The model was recalibrated for a panel format prior to unblinding the second cohort. The AUCs
overall were 0.81 and 0.77, and for squamous cell tumors alone were 0.89 and 0.87. The estimated negative
predictive value for a 15% disease prevalence was 93% overall and 99% for squamous lung tumors. The proteins
in the classifier function in destruction of the extracellular matrix, metabolic homeostasis and inflammation.
Conclusions: Selecting biomarkers resistant to sample processing variation led to robust lung cancer biomarkers that
performed consistently in independent validations. They form a sensitive signature for detection of lung cancer, especially
squamous cell histology. This non-invasive test could be used to improve the positive predictive value of CT screening,
with the potential to avoid invasive evaluation of nonmalignant pulmonary nodules.
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Lung cancer is the 5th leading cause of death worldwide.
There were 1.5 million lung cancer deaths in 2010, an
increase of 48% in the last 20 years [1]. Although lung
cancer death rates are declining in developed countries,
lung cancer incidence and death rates are rapidly rising* Correspondence: rostroff@somalogic.com
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unless otherwise stated.in the developing world, where smoking prevalence
continues to increase [2]. Most patients present with
advanced disease and 5-year survival rates are poor,
ranging from less than 10% in China to 13-16% in
Europe and the US [3-5].
The National Lung Screening Trial (NLST) demon-
strated that screening smokers and ex-smokers for lung
cancer can lead to early diagnosis and reduced lung
cancer mortality [6]. However, the low (4%) positiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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hort leads to a large number of unnecessary follow-up
procedures, including surgery for benign nodules, as was
first reported in the Pittsburgh Lung Screening Study
(PLuSS) and later in the NLST [6,7]. The European
NELSON CT screening study includes tumor volume
and doubling time in the assessment of pulmonary nod-
ules and improves the PPV to 41% by only referring
small nodules (50-500 mm3) for clinical follow-up if they
show evidence of growth and a doubling time of less
than 400 days [8,9].
Squamous cell carcinoma (SQ) accounts for approxi-
mately 30% of non-small cell lung cancer (NSCLC) cases
and is closely associated with long term tobacco expos-
ure while adenocarcinoma (AD) is the most common
form of NSCLC, even more so in never or light smokers
[10]. AD tumors often present in the periphery and are
the most prevalent histology detected by CT [11-13]. On
the other hand, SQ tumors typically arise in the central
airway and frequently are in close proximity to main
blood vessels [14], which may contribute to better detec-
tion of tumor biomarkers in the blood. SQ are the most
common NSCLC histology missed by CT [6,15], perhaps
because a central tumor location obscures CT detection
and because SQ tumors tend to have a rapid growth
rate that can lead to diagnosis as interval cancers
between scans. In a Taiwan population-based registry
of over 33,000 lung cancer patients, those with SQ
tumors had shorter median survival times than adeno-
carcinoma (AD) tumors [16].
Detterbeck and Gibson’s review of the natural history
of lung cancer reports that conventionally detected
NSCLCs have rapid doubling times averaging 135 days,
while those detected in CT screening programs have
substantially slower growth rates of 480 days [15]. They
also report that the average doubling time of AD is
576 days and SQ is 122 days, which is consistent with
twice as many SQ than AD detected as late stage disease
in CT screening [12]. The AD average doubling time is
longer than the cutoff for a positive screening result
established by the NELSON trial of 400 days [9]. Obser-
vations such as these have led to speculation that while
CT screening clearly leads to a mortality benefit for lung
cancer, the risk of over-diagnosis must be considered
[17,18]. In particular, 22% of NSCLC and 79% of
bronchioalveolar lung cancers detected by CT were
reported as indolent cancers and possible cases of
overdiagnosis [19]. Overdiagnosis of indolent cancers
may lead to increased costs, anxiety and harms from
unnecessary invasive procedures.
We previously reported the discovery of a protein bio-
marker panel for early detection of lung cancer [20]. We
also noted that several potential serum markers were
both lung cancer markers and markers of preanalyticvariability. Preanalytic bias in biomarker discovery stud-
ies is a well-known culprit contributing to failed valid-
ation studies [21]. This preanalytic variability can arise
from differences in blood sample collection, processing
and/or storage between study sites, or worse, introduce
case/control bias in samples collected differently at the
same study site, mimicking disease biomarkers. Such
markers will not correctly classify cases and controls in
independent validation studies nor will they produce ro-
bust clinical assays.
To better understand the effect of different blood sample
processing procedures, we evaluated protein measurement
bias in several clinical collections and controlled laboratory
studies [22-24]. These analyses revealed that perturbations
in serum processing protocols result in changes to many
proteins in a coordinated fashion. We subsequently devel-
oped protein biomarker signatures of processes such as cell
lysis, platelet activation and complement activation and
assembled these preanalytic signatures into quantitative
multi-dimensional Sample Mapping Vector (SMV) scores
[22]. The SMV score provides critical evaluation of the
quality of every blood sample used in discovery, and also
enables the evaluation of candidate protein biomarkers for
resistance to preanalytic variability.
Although the AUC of 0.9 in our original report for
both training and blinded verification was promising, we
had to eliminate some markers, such as HSP90, due to
preanalytic bias leading to site-to-site differences. When
the SMV scores of preanalytic effects were applied retro-
spectively, we found there were substantial center-
specific differences in preanalytic variation between
blood samples of cases and controls, leading to artificial
biomarker associations with lung cancer. As a result, our
initial diagnostic performance was partly dependent on
markers that not only related to cancer biology, but that
were also confounded by preanalytic case/control bias.
To eliminate this effect, we used the SMV score to de-
fine a fraction of the original sample set with minimal
differences in preanalytic variability between cases and
controls for biomarker discovery and classifier training.
The underlying platform technology used SOMAmers
(Slow Off-rate Modified Aptamers) as affinity reagents
to quantify 1033 proteins simultaneously with sub-pM
limits of detection and inter-assay CV of <5% [25,26]. The
7-marker classifier reported here performed consistently
through training and two independent blinded validation
studies, illustrating that robust biomarker discovery is en-
abled by both careful construction of clinical cohorts and
avoidance of preanalytic bias.
Results
Training a robust lung cancer classifier
In our initial lung cancer study we identified numerous
NSCLC biomarkers [20]. We also reported that this analysis
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study sites. This observation motivated a series of studies
investigating the effect of sample handling on biomarker
discovery [22,23]. The result of these studies was the devel-
opment of a set of SMVs which allowed us to quantify the
magnitude of confounding pre-analytical variation intro-
duced by sample collection differences.
For example, the cytoplasmic molecular chaperone
HSP90 is a well established lung cancer marker and
therapeutic target. We measured elevated levels of
HSP90 in the serum of lung cancer cases and included
it in our original classifier. However, HSP90 levels in
serum are affected by cell lysis during sample processing
and intracellular protein contamination leaking into serum,
causing a relative shift in the measured concentration. We
compared the distribution of HSP90 in the control group
by study sites (Figure 1a) and found that the mean level
varied by more than 2-fold across study sites. We con-
cluded that even though HSP90 is a strong lung cancer
marker, serum protein levels are confounded by preanalytic
variability and thus not robust enough for routine clinical
testing. These observations led us to embark on a new
effort to discover robust lung cancer biomarkers.
Using the cell contamination and complement SMVs,
we selected a subset of the original samples that were
uniformly collected. We also included a small set of
more variable samples to test the consistency of our
biomarkers. Samples were categorized as uniformlyHSP90
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Figure 1 Probability Density Function plots of HSP90 and MMP7
distributions for each training site control group. (a) HSP90 is an
example of a protein affected by preanalytic variability and the plot
demonstrates the bias between control groups. (b) MMP7, selected from
the high quality training samples, is consistent between sites.collected or variable based on empirically derived SMV
cutoffs, as described in the Methods section. This
strategy allowed us to discover robust biomarkers that
were not affected by sample handling. MMP7 is one of
the markers identified by this strategy. In contrast
to HSP90, the distribution of MMP7 across control
groups is consistent, demonstrating that this strategy
yielded biomarkers immune to common preanalytic
variability seen across different serum collections (con-
trast Figure 1a and b).
The training set consisted of 363 serum samples from
4 clinical sites (Table 1). The control population repre-
sents a high risk population for lung cancer and in-
cluded long term smokers, 45% with benign pulmonary
nodules. The intensity and duration of tobacco exposure
was balanced between the cases and controls. The cases
were 68% AD and 32% SQ, consistent with the current
US diagnosis pattern and 53% were localized, resectable
tumors (stages I and II).
We generated proteomic data with SOMAscan V2,
which measures 1033 analytes, an increase of 232 pro-
teins over V1 used in the original lung cancer studies
[20]. From this new analysis, we identified 15 candidate
biomarkers (Additional file 1) and built a 7-protein
Random Forest (RF) model with an AUC of 0.85 for all
training samples (Figure 2 and Table 2). Although 68%
of the cases were AD, the classifier was better at detect-
ing SQ with an AUC of 0.93 (Figure 2). The differential
expression of all of the classifier proteins was also
greater for SQ than AD compared to controls. Even
though the majority of cases were AD, models built from
the training data consistently performed better with SQ.
This led us to design a study to examine the histological
sensitivity.
Validation studies and histological performance
To precisely determine the histological sensitivity of the
classifier, we designed a nested case/control study from
samples obtained from the University Hospital Heidelberg
(UHH) that balanced stage and AD/SQ histology. A small
number of benign nodule controls were included to verify
specificity. This independent, blinded study confirmed the
performance established in training with an AUC of 0.81.
The AUC increased to 0.89 when only the SQ cases were
considered (Figure 3).
A second independent, blinded validation study was
performed with a reference set from the National Cancer
Institute (NCI) Early Detection Research Network (EDRN)
designed to validate candidate lung cancer markers for
diagnosis of pulmonary nodules. The 63 cases were 46%
Stage I/II AD and 29% Stage I/II SQ. Late stage cases made
up 25% of the cohort and were approximately equally dis-
tributed between AD and SQ. The controls were smokers
who had undergone radiologic testing for suspicion of lung
Table 1 Demographics of training and validation study cohorts
Characteristic Training (n = 363) UHH validation (n = 138) EDRN validation (n = 135)
Case Control Case Control Case Control
No. subjects 94 269 111 27 63 72
Median age (years) 69 57 62 58 68 71
Interquartile range 63-74 52-64 54-70 51-71 62-74 66-76
Gender
Male 42 126 70 13 36 39
Female 52 143 41 14 27 33
Median pack-years* 40 40 35 30 60 38
Interquartile range 23-57 20-56 20-50 18-43 40-76 34-60
Histopathology/Stage
Adenocarcinoma 64 55 38
I 27 19 24
II 7 16 5
III 19 20 7
IV 11 0 2
Squamous cell 30 56 25
I 11 20 14
II 5 16 4
III 12 20 3
IV 2 0 4
Benign nodule 122 27 20
*Pack-years is defined as the product of the total number of years of smoking and the average number of packs of cigarettes smoked daily.
Smoking data was not available for 8 subjects in training, 21 in UHH and 10 in EDRN studies.
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Figure 2 Training set ROC. Results are plotted for the entire data
set and for AD and SQ tumor histologies separately.
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AUC for all samples in this study was 0.77, which is sta-
tistically equivalent to the training set (Figure 4). Only
33% of these samples would fall into the “good” processing
quality category based on SMV analysis, yet the results were
equivalent to the training set, supporting our hypothesis
that selecting markers robust to sample variability would
result in a validated classifier. Dividing the cases by hist-
ology, the AUC for SQ was 0.87 and 0.70 for AD.
The goal of lung cancer early detection is to identify
the malignancy at the stage where surgical cure is pos-
sible. To illustrate the utility of our test for this clinical
application, we divided test performance by stage and
histology for each clinical cohort (Table 3). Sensitivity
for detection of stage I AD ranged from 33-50% and
stage I SQ was 64-93%. Sensitivity increased with lung
cancer stage, illustrating that the markers correlate with
disease burden. Sensitivity for detection of stages II-IV
ranged from 51-79% for AD and 82-84% for SQ. Assu-
ming a 15% prevalence rate based on NLST data for 11-
30 mm pulmonary nodules [27], the estimated positive
predictive value (PPV) for the EDRN validation set is
30% and the negative predictive value (NPV) is 93%.
Considering each histology separately and halving the
prevalence to 7.5%, the SQ PPV is 20% and the NPV is
Table 2 Lung cancer classifier proteins ranked by gini importance score
Protein
[Entrez gene ID]
Name Gini importance Function Up/down
in NSCLC
MMP12 [4321] Matrix metallo-peptidase 12 20.33 Breakdown of extracellular matrix, positive regulation
of cell proliferation, tissue injury and remodeling
Up
SERPINA3 [12] Apha-1 antiproteinase 14.11 Serine protease inhibitor, part of acute phase response
and tissue homeostasis
Up
MMP7 [4316] Matrix metallo-peptidase 7 13.73 Breakdown of extracellular matrix, positive regulation of
cell proliferation, collagen catabolism, degrades fibronectin
Up
C9 [735] Complement component 9 11.31 Inflammatory acute phase reactant, pore-forming subunit
of cytolytic MAC complex
Up
CRP [1401] C-reactive protein 11.01 Inflammatory acute phase reactant, immune effector Up
CNDP1 [84735] Carnosine dipeptidase 1 8.66 Carboxypeptidase, functions in amino acid transport
and metabolism
Down
CA6 [765] Carbonic anhydrase VI 7.62 Reversible hydratation of carbon dioxide,
one-carbon metabolism, nitrogen metabolism
Down
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15%/96%. The higher estimated PPV and NPV for SQ
may relate to the faster doubling time of this aggressive
tumor leading to release of greater quantities of bio-
marker proteins into the blood.
The proteins in the classifier function in destruction
of the extracellular matrix, metabolic homeostasis and
inflammation. MMP7 and MMP12 levels are elevated
in lung cancer, which may facilitate breakdown of the
extracellular matrix and tumor spread. The two meta-
bolic enzymes in the classifier, CNDP1 and CA6, are
lower in the serum of lung cancer patients, perhaps in
response to the low pH created by increased tumor
glycolysis. The proteins related to host defense, CRP,
C9 and SERPINA3, are elevated in lung cancer and0.0 0.2 0.4 0.6 0.8 1.0
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Figure 3 UHH validation ROC. Results are plotted for the entire
data set and for AD and SQ tumor histologies separately.may arise from tumor-induced stromal inflammation.
The functions represented by these biomarkers are
predominant hallmarks of neoplastic growth and ma-
lignant spread. When measured together they form a
sensitive signature for detection of NSCLC.Discussion
The successful validation of biomarker studies depends
on two key aspects of biomarker discovery: identifying
biomarkers in clinically relevant cohorts and controlling
preanalytic sample variability that may introduce bias in
the apparent disease biomarkers. We have described a
series of studies for discovery and validation of a NSCLC
classifier that mirrors the intended clinical use of these0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
EDRN Validation
1−Specificity
S
en
si
tiv
ity AUC: 0.769 +/− 0.08
AUC: 0.703 +/− 0.10
AUC: 0.869 +/− 0.08
NSCLC
AD
SQ
Figure 4 EDRN validation ROC. Results are plotted for the entire
data set and for AD and SQ tumor histologies separately.
Table 3 Performance of the classifier in training and validation studies
Sensitivity (%) Specificity (%)
Stage I Stage II-IV Controls
AD SQ AD SQ Benign nodule All controls
Data set
Training set 33 64 59 84 89 90
95% CI 19-52 35-85 43-74 62-95 82-93 86-93
UHH validation 35 75 51 83 81 81
95% CI 18-57 53-89 36-67 68-93 63-92 63-92
EDRN validation 50 93 79 82 70 71
95% CI 31-69 66-100 52-93 51-96 48-86 59-80
Sensitivity of the classifier in training and validation is calculated by tumor stage and histology. Specificity is calculated for the benign nodule subset and for all
controls. 95% CI is the 95% confidence interval.
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Realizing that some of the serum lung cancer biomarkers
in our previously reported classifier [20] were influenced
by bias that was related to blood processing differences,
such as contamination by intracellular proteins caused by
cell lysis during processing, we set out to identify a new
set of unbiased markers. Applying quantitative SMV mea-
sures of preanalytic variability, we identified preanalytic
sample variation that revealed unintentional differences
inherent in how biological samples are obtained, proc-
essed and stored. We discovered 15 NSCLC biomarkers
with a well-collected sample set from 4 independent study
sites that continued to perform across a wide spectrum of
sample handling parameters. Nine of these were also iden-
tified in our original study [20]. From these 15 biomarkers,
a robust 7-marker random forest (RF) classifier was devel-
oped with an AUC of 0.85 in training. The reliability and
consistency of this classifier was demonstrated in two in-
dependent blinded validation studies with an AUC of 0.81
in the histologically balanced UHH study and 0.77 in the
EDRN indeterminate pulmonary nodule cohort. The clas-
sifier sensitivity correlates with cancer stage, meaning that
the biomarker levels are proportional to the extent of dis-
ease burden. We have observed that biomarkers that do
not correlate with disease burden may be influenced by
preanalytic bias or demographic case/control differences.
At an estimated prevalence of 15%, our PPV/NPV in
the EDRN validation study was 30%/93% over all histol-
ogies. This is an improvement over the 85% NPV if all
nodules were considered benign at this prevalence. To
estimate NPV separately for each histology, we reduced
the prevalence to 7.5% and calculated an NPV of 96%
for AD and 99% for SQ, suggesting the classifier will aid
in discriminating the large number of CT-identified
benign nodules from true NSCLC. The consistent per-
formance of our classifier established in training and
maintained in two blinded validation studies with samplesfrom independent study sites demonstrates the strength of
our biomarker identification strategy. Choosing reliable bio-
markers resistant to preanalytic variation led to a robust
classifier. Consistency from training to validation has met
with difficulty in other recent lung cancer biomarker re-
ports, where a significant drop in the AUC from training to
validation was reported [28,29].
We observed that quantitative measurement of well
established lung cancer markers such as HSP90 can be
influenced by variation in sample handling that causes
an imbalance in distribution between cases and controls
across study sites. This observation is similar to changes
in cytokine measurements reported by Pine et al. [30].
These authors describe different cytokine concentration
ranges in two large lung cancer cohorts, NCI-MD and the
Prostate Lung Colorectal and Ovarian Cancer Screening
Trial (PLCO), making it difficult to use the same case/
control cutoffs for both study populations. They postu-
late that differences in sample handling may contribute
to this bias and suggest that follow-up studies investi-
gate standardization methods for measuring these
markers. We have opted for a different solution – se-
lect robust markers that are resistant to measurement
drift caused by preanalytic sample processing differ-
ences. While this approach may sacrifice some per-
formance, the gain in reliable measurements is critical
for ultimate success in the clinical setting.
The proteins in our classifier are related to the biology
of tumor growth and function to sustain proliferation
and activate invasion (MMP7 and MMP12), and respond
to oxidative stress and deregulation of cellular energetics
(CNDP1 and CA6). The supportive role of the tumor
micro-environment is represented by proteins involved
in avoiding immune destruction and inducing tumor-
promoting inflammation (CRP, C9, SERPINA3). Exten-
sive genomic characterization of SQ lung cancers by
The Cancer Genome Atlas Research Network (TCGA) re-
vealed dysfunctions in genes involved in these processes,
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apoptotic signaling and avoiding immune detection and
destruction [31].
The matrix metalloproteinases are critically important
for extracellular matrix remodeling. Proteolytic matrix
degradation by the MMPs promotes tumor growth, inva-
sion and angiogenesis [32]. Overexpression of MMP7
correlates with poor NSCLC prognosis [32,33]. MMP12
expression may be induced by smoking and trigger inflam-
mation, leading to emphysema and lung cancer in mouse
models of inflammatory triggers of oncogenesis [34].
The two metabolic enzymes, CNDP1 and CA6, are
both down-regulated in our NSCLC studies. CNDP1
cleaves carnosine. Lower CNDP1 activity may lead to
higher levels of carnosine, which is a scavenger of react-
ive oxygen species (ROS) and nitrogen species [35]. Car-
nosine can also act as a hydrogen ion buffer. CA6 is the
secreted isoform of carbonic anhydrase, and it is in-
volved in pH, respiration and CO2 homeostasis [36].
The catalytic activity of each of these enzymes releases a
proton and lowers the local pH. Tumors are often hyp-
oxic and have an acidic pH as a byproduct of increased
glycolysis (the Warburg effect [37]). We speculate that
lowering the activity of both of these enzymes could
counteract the low pH produced by increased glycolysis
in tumors.
Smoking causes chronic inflammation and release of
ROS, which plays an important role in tumorigenesis. In-
creased macrophage and neutrophil infiltration results in
an increase in cytokines, growth factors and mediators of
inflammation that can induce epithelial-mesenchymal tran-
sition and destruction of host cell-mediated immune re-
sponses, leading to lung carcinogenesis [38]. Three of the
classifier markers, CRP, C9 and SERPINA3, function in the
acute phase host response and inflammation. CRP has long
been associated with lung cancer risk and prognosis
[30,39,40]. Recently Shiels and colleagues reported that ele-
vated circulating inflammation markers are associated with
lung cancer risk, with CRP having the highest risk related
odds ratio [41].
The complement cascade may contribute to tumor
growth by promoting acute and chronic inflammation
and by facilitating cellular proliferation and invasion
[42]. The membrane attack complex (MAC) is the ter-
minal event of the complement cascade, forming a pore
in the cell membrane leading to target cell death. The
MAC is composed of C5b, C6, C7, C8 and multiple C9
molecules, and has been shown to promote extracellu-
lar matrix disintegration, leading to invasion and me-
tastasis [42].
Lastly, SERPINA3 is a member of the alpha-1 antipro-
teinase family and member of the serine protease inhibi-
tor class. Other members of this family have also been
reported as serum biomarkers for lung cancer [39,43].These proteins function in the host defense against the
tumor and increasing levels in the blood arise from
migration of inflammatory cells into the tumor and
systemic innate and adaptive responses.
A limitation of this study is that the biomarkers were
selected to perform well across both AD and SQ tumors
and that detection of other histological classes was not
assessed. In light of the emerging genetic profiles from
the TCGA Network and driver mutation divergence
based on histology, training for AD and SQ separately
could reveal histology-specific biomarkers and improve
early stage detection for both tumor types. A potential
limitation of incorporating host response markers into
the classifier is lack of specificity. However, by incorpor-
ating multiple proteins into a classifier, rather than rely-
ing on a single biomarker, the resultant algorithm can
add disease specificity. Another emerging strategy for
improving biomarker panel accuracy is to incorporate
biomarker measurements with clinical risk factors, par-
ticularly in the management of indeterminate pulmonary
nodules [44-46].Conclusions
A major strength of our classifier is the sensitive detection
of early stage tumors, and in particular Stage I SQ. Typic-
ally, SQ grows rapidly and is most often diagnosed at a late
stage. Both the fast doubling time and central location com-
plicate CT detection of SQ lung cancers. The validated test
described here could complement CT by identifying indi-
viduals at the highest risk and improve early detection
of these aggressive lung tumors. Optimizing identification
of rapidly growing tumors may also reduce over-diagnosis
of indolent disease.
This study highlights the importance of sample quality
assessment using a tool for evaluating bias in case/con-
trol studies before proceeding to biomarker discovery.
Choosing biomarkers with not just the best case/control
discrimination but that are also resistant to sample pro-
cessing variation increases the likelihood that a robust
biomarker panel will consistently perform well in the
intended clinical setting.
Methods
Objectives
The objective of this study was to apply the SOMAscan
proteomic assay to discover and validate serum biomarkers
for detection of NSCLC in current and former smokers
who are at high risk for lung cancer, and to perform subset
analysis based on histopathologic classification.
Participants
Three prospectively designed case/control studies were
performed from archived samples (Table 1). A multi-
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classifier training followed by two independent blinded
validation studies from archived collections assembled
by the Thoraxklinik at UHH and the EDRN (Figure 5).
Inclusion criteria for cases in all three studies were: (1)Figure 5 Study flowchart for biomarker discovery and
validation studies.diagnosis of primary lung cancer pathologically con-
firmed as either AD or SQ (2) no prior history of lung
or other cancer except non-melanoma skin cancer in
the last 5 years and (3) serum collected within one year
of diagnosis and prior to lung cancer treatment. All con-
trols were smokers (current or former) or had a lung le-
sion on chest X-ray or CT suspicious for lung cancer
and proven not to be cancer by either biopsy or 1 year
clinical follow-up. Demographic data was collected by
self-report questionnaires. Additional data for cases were
acquired through clinical chart review.
Training samples were collected at 4 study centers as
previously described [20]: NYU Langone Medical and
Cancer Center (NYU), University of Pittsburgh Cancer
Institute (PITT), Roswell Park Cancer Institute (RPCI),
and Bioserve (BS). The sample cohort included cases
and controls from each study center. Serum was col-
lected from cases within 8 weeks of first biopsy-proven
lung cancer diagnosis. Cases were diagnosed with patho-
logic or clinical stage I-IV NSCLC. The high-risk control
population had a history of long-term tobacco use, in-
cluding active and ex-smokers with ≥10 pack-years of
cigarette smoking and those with benign pulmonary
nodules. Sample selection for this study was based on
our sample quality metric, described below.
The UHH validation study is a nested case/control study
designed to assess the histopathological performance of the
classifier. Samples were obtained from the Biobank at
Thoraxklinik Heidelberg, Member of the Biomaterial
Bank Heidelberg and the Biobank Platform of the German
Centre for Lung Research. Approximately equal numbers
of AD and SQ cases were analyzed to measure sensitivity
and a small number of benign nodule controls were in-
cluded to confirm specificity. The samples were collected
from patients undergoing lung cancer diagnostic proce-
dures at the Thoraxklinik; no minimum tobacco use cri-
teria were applied.
The EDRN validation study cohort was assembled by
the Lung Cancer Biomarker Group as a multicenter ref-
erence set for validating biomarkers for detection of lung
cancer [47]. Samples were provided by the NCI on be-
half of the EDRN. Inclusion criteria were as described
above and serum collected from patients with abnormal
chest X-ray or CT or at high risk for lung cancer and
age ≥50 with ≥30 pack years of tobacco use. The EDRN
validation study is designed to represent the population
most likely to benefit from a lung cancer diagnostic test
[47]. These demographics are similar to those used in
the NLST study, which had a prevalence of lung cancer
of 1.1% in the CT screening group [6,48].
Ethics
All samples and clinical information were collected
under Health Insurance Portability and Accountability
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obtaining written informed consent under clinical re-
search protocols approved by appropriate institutional
review boards (IRBs): The University of Pittsburgh IRB
(PITT); The New York University School of Medicine
IRB (NYU); The Roswell Park Cancer Institute IRB
(RPCI); The Cape Cod Healthcare IRB (BS), and Western
IRB (UHH and EDRN).
Sample collection procedure
Serum samples were collected following uniform pro-
cessing protocols recommended by the EDRN [49]. All
samples were allowed to clot and serum was recovered
by centrifugation within 2–8 hours of collection and
stored at −80°C. HIPAA compliant, de-identified samples
were shipped frozen on dry ice to SomaLogic from the
study centers. Samples were thawed twice for aliquoting
(once at the site and once at SomaLogic) prior to prote-
omic analysis.
Sample blinding
To prevent potential bias, a unique barcode was
assigned to each sample and data record, and the key was
stored in a secure database accessible only to designated
study administrators. The sample blinding code was broken
according to the pre-specified analysis plan. First the train-
ing set was unmasked for training the classifier. Then the
biomarkers and classifier were fixed and the UHH samples
were unblinded by designated study investigators. Finally,
the EDRN validation set was unblinded by the Data
Management and Coordinating Center of the EDRN
after they received the classifier prediction results.
Proteomic analysis
Serum samples (15 μl) were analyzed on the SOMAscan
V2 proteomic assay, which measures 1033 proteins
[25,50]. The SOMAscan analytes cover a broad range of
proteins associated with disease physiology and biological
functions, including cytokines, kinases, growth factors,
proteases and their inhibitors, receptors, hormones and
structural proteins [23]. SOMAscan uses novel modified
DNA aptamers called SOMAmers to specifically bind pro-
tein targets in biologic samples [25,26]. All sample analyses
were conducted in the Good Laboratory Practice (GLP)
compliant lab at SomaLogic by trained staff as described
[51]. Serum samples were distributed randomly in 96-well
microtiter plates and the assay operators were blinded to
case/control identity of all samples. Data for the training
and two validation studies were generated in separate assay
runs. Serum samples from the EDRN study were assayed
with a panel assay format [51] consisting of 81 SOMAmers
including the 15 candidates identified in training. A subset
of the training samples was re-assayed in this format to ad-
just model coefficients prior to unblinding. The trainingand validation assay data are provided as Additional file 2
(UHH) and Additional file 3 (EDRN). Assay results are re-
ported in Relative Fluorescence Units (RFU). Data process-
ing was as described by Gold et al. [25]. Briefly, microarray
images were captured and processed with a microarray
scanner and associated software. Each sample in a study
was normalized by aligning the median of each sample to a
common reference. Inter-plate and inter-run calibration
was done by applying a multiplicative scaling coefficient to
each SOMAmer. These scaling factors were calculated
using the eight reference calibrators on each plate.
Sample quality assessment
Based on clinical and experimental observations, we
have developed a series of protein panels and quality
scores called SMVs to characterize potential preanalytic
variability imparted by blood sample collection and pro-
cessing [22-24]. We reported preanalytic case/control
bias and site-to-site bias in a comparison of the four
clinical sites in our initial lung cancer study [20] and
proteins that changed with sample processing parame-
ters such as storage and clotting time, centrifugation
force, and temperature [22-24]. Three SMVs were devel-
oped from these studies that typify blood components
affected by sample handling: complement (4 proteins,
primarily C3 and its proteolytic fragments), cell contam-
ination (30 intracellular leukocyte proteins released
through cell lysis), and platelet contamination (16 proteins
released through activation or lysis) (Additional file 4).
All three SMVs can be applied to plasma, but only the
complement and cell contamination SMVs are applic-
able to serum since platelets are activated in the clotting
process. SMVs are used in two ways: (1) to assess the
quality of sample collection and quality differences be-
tween study sites or cases and controls within a site and
(2) to select robust biomarkers that are insensitive to
preanalytic variation. Biomarkers that correlate with the
SMVs should not be selected unless strict sample pro-
cessing parameters can be employed uniformly. The
complement and cell contamination SMVs were applied
to samples from the 4 training sites to select the cohort
for biomarker discovery and classifier training. Cutoffs
were assigned empirically based on experimental data
[22,23]. Sample quality was assessed for the validation
studies, but no samples were excluded from analysis
based on low quality.
Candidate biomarker selection and classifier training
Based on the composite SMV score, 80% of the training
samples were categorized as high quality and 20% as low
quality but still within the sample processing protocol
requirements. The rationale for selecting robust, disease
specific biomarkers was to identify biomarker candi-
dates in uniformly well collected samples that had little
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but ensure that these biomarkers performed consistently
in lower quality samples. We have observed that classifiers
trained within a sample set culled using SMVs generalize to
samples outside the set, however performance degradation
is sometimes observed as the sample quality degrades.
We performed non-parametric Kolmogorov-Smirnov
(KS) tests to identify 15 differentially expressed analytes
(Additional file 1) [19,29]. A RF classifier was built from
the panel of candidate biomarkers using a backward
elimination procedure that utilized the gini importance
measure provided by the RF classifier [52,53]. RF is a
decision-tree based method and predictions are influ-
enced by the gini importance score of each biomarker.
To improve training prediction accuracy, iterative boot-
strap aggregation, or bagging, combined with out of bag
error estimation was used to reduce the training vari-
ance [53]. The gini importance is a measure of the
effectiveness of a biomarker for correctly classifying
samples in the training set and can be used to eliminate
markers that are less vital to the performance of the
classifier. The backward elimination procedure was initi-
ated by building a RF classifier that included all candi-
date biomarkers. The least important biomarker was
then eliminated and a new model was built with the
remaining biomarkers. This procedure continued until
only single biomarkers remained. The final 7-marker
panel was selected because it provided the best balance
between the highest AUC and the lowest number of
markers in the model. RF case/control prediction prob-
ability scores span from 0 to 1, and for binary performance
estimations we selected a case threshold of 0.45 or greater.
The final classifier was then applied to make blinded pre-
dictions on the two independent validation sets.
The study design and execution were conducted ac-
cording to accepted best practices [54]. Analyses were
performed with R statistical software version 2.10.1.
Functional analysis was performed with DAVID Bio-
informatics Resources version 6.7 [55].
Additional files
Additional file 1: Candidate protein biomarkers identified in training.
Additional file 2: UHH Validation, attached as separate csv file.
Training and validation data for the UHH validation study.
Additional file 3: EDRN Validation, attached as separate csv file.
Training and validation data for the EDRN validation study. A subset of
the original training samples was repeated in this study to calibrate the
model for the panel format, and this data is included in Additional file 3.
Additional file 4: Protein components of the SMV vectors.
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